BB BIOTECH NAM. SF 0,20/ CH0038389992 /
| 6/17/2025 8:05:14 AM | Chg. -1.1000 | Volume | Bid9:04:00 AM | Ask9:15:01 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 31.2000EUR | -3.41% | 0 Turnover: 0.0000 |
31.2000Bid Size: 250 | 31.4000Ask Size: 200 | 1.74 bill.EUR | - | - |
Assets
|
2020 US GAAP in mill. CHF |
2021 IFRS in mill. CHF |
2022 IFRS in mill. CHF |
2023 IFRS in mill. CHF |
2024 IFRS in mill. CHF |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | - | - | - | - | - | ||||||
| Intangible Assets | - | - | - | - | - | ||||||
| Long-Term Investments | 0.0000 | 0.0000 | - | 2,634.7140 | 1,406.8810 | ||||||
| Fixed Assets | 0.0000 | 0.0000 | - | - | - | ||||||
| Inventories | - | - | - | - | - | ||||||
| Accounts Receivable | - | - | - | 1.8290 | 0.0000 | ||||||
| Cash and Cash Equivalents | 6.8000 | 2.8000 | 1.9500 | .5010 | .4580 | ||||||
| Current Assets | 3,963.1000 | 3,644.1000 | 3,053.3900 | - | - | ||||||
| Total Assets | 3,963.1000 | 3,644.1000 | 3,053.3900 | 2,637.1540 | 2,407.3990 | ||||||
Liabilities
|
2020 US GAAP in mill. CHF |
2021 IFRS in mill. CHF |
2022 IFRS in mill. CHF |
2023 IFRS in mill. CHF |
2024 IFRS in mill. CHF |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | - | - | - | 5.4360 | 0.0000 | ||||||
| Long-term debt | - | - | - | - | - | ||||||
| Liabilities to Banks | 63 | 355 | - | - | - | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 75.6000 | 360.6000 | 367.2500 | 313.9370 | 121.1070 | ||||||
| Share Capital | - | 11.0800 | - | - | - | ||||||
| Total Equity | 3,887.5000 | 3,283.5000 | 2,686.1400 | 2,323.2170 | 2,286.2920 | ||||||
| Minority Interests | - | - | - | 0.0000 | 0.0000 | ||||||
| Total liabilities equity | 3,963.1000 | 3,644.1000 | 3,053.3900 | 2,637.1540 | 2,407.3990 | ||||||
Income Statement
|
2020 US GAAP in mill. CHF |
2021 IFRS in mill. CHF |
2022 IFRS in mill. CHF |
2023 IFRS in mill. CHF |
2024 IFRS in mill. CHF |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 741.8000 | .0100 | 1.2600 | .5300 | - | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | 691.2000 | -404.7000 | - | - | 112.2370 | ||||||
| Interest Income | - | - | - | - | - | ||||||
| Income Before Taxes | 691.2000 | -404.7000 | -357.7500 | -206.5280 | 75.9530 | ||||||
| Income Taxes | .0800 | .0700 | -61 | .0790 | .0540 | ||||||
| Minority Interests Profit | - | - | - | 0.0000 | 0.0000 | ||||||
| Net Income | 691.2000 | -404.8000 | -357.8100 | -206.6070 | 75.8990 | ||||||
Per Share
Cash Flow
|
2020 US GAAP in mill. CHF |
2021 IFRS in mill. CHF |
2022 IFRS in mill. CHF |
2023 IFRS in mill. CHF |
2024 IFRS in mill. CHF |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 262.4000 | -94.8000 | 231.1300 | 218.2760 | 304.5600 | ||||||
| Cash Flow from Investing Activities | - | - | - | - | - | ||||||
| Cash Flow from Financing | -284.5000 | 91.8000 | -233.2700 | -220.2130 | -305.2020 | ||||||
| Decrease / Increase in Cash | -23.9000 | -4 | - | - | - | ||||||
| Employees | - | - | - | 94 | 86 | ||||||
